Insulin Efsitora Alfa + Insulin Degludec

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes

Conditions

Diabetes, Type 2 Diabetes

Trial Timeline

Jun 3, 2022 โ†’ Apr 10, 2024

About Insulin Efsitora Alfa + Insulin Degludec

Insulin Efsitora Alfa + Insulin Degludec is a phase 3 stage product being developed by Eli Lilly for Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT05362058. Target conditions include Diabetes, Type 2 Diabetes.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT05463744Phase 3Completed
NCT05362058Phase 3Completed
NCT05275400Phase 3Completed